Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

NuVasive Announces New Organizational Structure, Streamlined Leadership Team

NuVasive announced a new organizational structure and associated executive team selected by Chief Executive Officer J. Christopher Barry.

Mr. Barry succeeded Gregory T. Lucier as NuVasive’s CEO, effective November 5, 2018.

“Our new structure will enable us to better capitalize on this talent by fostering cross-functional collaboration, consolidating complementary functions and increasing accountability,” Mr. Barry said in a press release.

Mr. Barry, who most recently served as a senior vice president at Medtronic, has kept most NuVasive executives in place and expanded  certain of their roles. The following people will report directly to Mr. Barry. These personnel changes went into effect January 3:

  • Matt Link, promoted to President in November, will continue to serve in that role, but in an expanded capacity to include direct management of NuVasive Clinical Services and Global Logistics.

  • Jim Garrett, Chief Compliance Officer and leader of the company’s Global Risk and Integrity (GRI) function, will assume an expanded role overseeing Business and Quality Systems functions, including GRI, Regulatory Affairs/Quality Affairs, Information Technology and Environmental Health & Safety.

  • Lucas Vitale is named Chief Human Resources Officer. Mr. Vitale most recently served as Vice President, Human Resources and Sales Training.

  • Dale Wolf will continue to oversee the company’s manufacturing efforts, including the facility in West Carrollton, Ohio. Mr. Wolf was hired in 2H18 and is a former GE executive with 20 years of medical device manufacturing experience. As noted in its 3Q18 earnings call, by the end of 2018, NuVasive anticipates producing about 70% of the SKUs planned for self-manufacture.

  • Raj Asarpota will continue to serve as Executive Vice President and Chief Financial Officer.

  • Nate Sisitsky will continue to serve as General Counsel and Corporate Secretary and lead the company’s legal department as well as the NuVasive Spine Foundation. Mr. Sisitsky will also oversee the company’s Real Estate and Facilities function.

  • Suzanne Hatcher will continue to lead the company’s Internal and External Affairs functions, including Investor Relations, Public Relations and Internal Communications.

  • The positions of Executive Vice President, People and Culture and Executive Vice President, Global Process Transformation, previously held by Pete Leddy and Stephen Rozow, respectively, have been eliminated.

NuVasive’s Global Commercial regional leaders include Paul McClintock (U.S.), Erin McEachren (Europe), Takaaki Tanaka (Japan/China) and Jim Abraham (Australia/New Zealand).

NuVasive has continued to perform above market growth as its undergone multiple transitions at the CEO and executive leadership levels since 2015. The company announced preliminary 4Q18 revenue of $288MM, +6% vs 4Q17, and full year 2018 revenue of $1,102MM, +7.2% vs. 2017. The company is slated to report full revenue results in late February.

Rob Meyer is ORTHOWORLD’s Senior Editor. Please send comments on this article to This email address is being protected from spambots. You need JavaScript enabled to view it..